Discover a new option for mNSCLC patients
with EGFR Exon20 Insertions

Clinical perspective presented by:

Mark A. Socinski, MD

Executive Medical Director
Member, Thoracic Oncology Program
AdventHealth Cancer Institute

Erminia Massarelli, MD, PhD, MS

Associate Professor
City of Hope Comprehensive Cancer Center


Program Objectives

Explore EGFR Exon20 Insertion+ mNSCLC

Review guideline-recommended testing

Demonstrate how a new treatment option is designed for EGFR Exon20 insertion mutations

Review the dosing safety and efficacy of a new treatment option


takedaoncology

All trademarks are the property of their respective owners.
©2021 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved. 09/21 USO-NON-0334